PDL BioPharma, Inc. (NASDAQ:PDLI) is set to announce third quarter earning results on Monday 9th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, PDLI to report 3Q20 income of $ 0.06 per share.
For the full year, analysts anticipate top line of $ 23.15 million, while looking forward to loss of $ 0.54 per share bottom line.
Previous Quarter Performance
PDL BioPharma, Inc. unwinded loss for the second quarter of $ 0.20 per share, from the revenue of $ 5.21 million. The quarterly revenues declined 30.16 percent compared with the same quarter last year. Wall street analysts are predicting, PDLI to report 2Q20 income of $ 0.10 per share from revenue of $ 1.50 million. The bottom line results missed street analysts by $ 0.3 or 300 percent, at the same time, top line results outshined analysts by $ 3.71 million or 247.33 percent.
Stock Performance
On Friday, shares of PDL BioPharma, Inc. has traded high as $ 2.26 and has cracked $ 2.23 on the downward trend, reaching $ 2.24 with volume of 410.70 thousand shares.
According to the previous trading day, closing price of $ 2.24, representing a 7.18 % increase from the 52 week low of $ 2.09 and a 41.97 % decrease over the 52 week high of $ 3.86.
The company has a market capital of $ 255.32 million and is part of the Healthcare sector and Biotechnology industry.
PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in the United States, Europe, and internationally. The company operates in three segments: Pharmaceutical, Medical Devices, and Income Generating Assets.
